Codexis, Inc., a biotechnology company headquartered in Redwood City, United States, operates within the Health Care sector, specifically under the Life Sciences Tools & Services industry. The company is publicly traded on the Nasdaq exchange, with its financial activities denominated in USD. As of April 8, 2026, Codexis’s stock closed at $2.4, reflecting a significant fluctuation over the past year. The company’s 52-week high was recorded at $3.87 on August 13, 2025, while its 52-week low was $0.96 on March 3, 2026. The market capitalization of Codexis stands at approximately $179.92 million.
Codexis is renowned for its specialization in developing biocatalysts, which are pivotal in the pharmaceutical and fine chemicals industries. The company’s core technology facilitates the scale-up and implementation of biocatalytic solutions, catering to the manufacturing processes of its global clientele. This innovative approach allows Codexis to offer tailored solutions that enhance the efficiency and sustainability of chemical production.
Despite its technological advancements and strategic positioning within the biotechnology sector, Codexis faces financial challenges, as indicated by its price-to-earnings ratio of -3.85. This negative ratio suggests that the company is currently not generating profits, which may be attributed to various factors, including research and development expenses, market competition, or broader economic conditions affecting the biotechnology industry.
Codexis’s commitment to advancing biocatalytic technology underscores its potential to influence the pharmaceutical and fine chemicals sectors significantly. By enabling more sustainable and efficient manufacturing processes, the company aims to address the growing demand for environmentally friendly production methods. As Codexis continues to navigate the complexities of the biotechnology landscape, its ability to innovate and adapt will be crucial in determining its future trajectory and financial performance.
